Search Results - "CATER, Nilo B" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

Comparison of Atorvastatin 80 mg/day Versus Simvastatin 20 to 40 mg/day on Frequency of Cardiovascular Events Late (Five Years) After Acute Myocardial Infarction (from the Incremental Decrease in End Points Through Aggressive Lipid Lowering [IDEAL] Trial)

by Pedersen, Terje R., MD, PhD, Cater, Nilo B., MD, Faergeman, Ole, MD, DMSc, Kastelein, John J.P., MD, PhD, Olsson, Anders G., MD, PhD, Tikkanen, Matti J., MD, PhD, Holme, Ingar, PhD, Larsen, Mogens Lytken, MD, DMSc, Lindahl, Christina, MD, Szarek, Michael, PhD
Published in The American journal of cardiology (01.08.2010)

Get full text

Journal Article

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

by Cosentino, Francesco, Cannon, Christopher P, Cherney, David Z.I, Masiukiewicz, Urszula, Pratley, Richard, Dagogo-Jack, Sam, Frederich, Robert, Charbonnel, Bernard, Mancuso, James, Shih, Weichung J, Terra, Steven G, Cater, Nilo B, Gantz, Ira, McGuire, Darren K
Published in Circulation (New York, N.Y.) (08.12.2020)

Get full text

Journal Article

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial

by Ezekowitz, Michael D, Pollack, Charles V, Halperin, Jonathan L, England, Richard D, VanPelt Nguyen, Sandra, Spahr, Judith, Sudworth, Maria, Cater, Nilo B, Breazna, Andrei, Oldgren, Jonas, Kirchhof, Paulus
Published in European heart journal (21.08.2018)

Get full text

Journal Article

Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)

Comparison of Efficacy and Safety of Atorvastatin (80 mg) to Simvastatin (20 to 40 mg) in Patients Aged <65 Versus ≥65 Years With Coronary Heart Disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] Study)

by Tikkanen, Matti J., MD, PhD, Holme, Ingar, PhD, Cater, Nilo B., MD, Szarek, Michael, PhD, Faergeman, Ole, MD, DMSc, Kastelein, John J.P., MD, PhD, Olsson, Anders G., MD, PhD, Larsen, Mogens Lytken, MD, DMSc, Lindahl, Christina, MD, Pedersen, Terje R., MD, PhD
Published in The American journal of cardiology (01.03.2009)

Get full text

Journal Article

Behenic acid is a cholesterol-raising saturated fatty acid in humans

Behenic acid is a cholesterol-raising saturated fatty acid in humans

by CATER, Nilo B, DENKE, Margo A
Published in The American journal of clinical nutrition (2001)

Get full text

Journal Article

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus

by Liu, Jie, Patel, Shrita, Cater, Nilo B., Wu, Larry, Huyck, Susan, Terra, Steven G., Hickman, Anne, Darekar, Amanda, Pong, Annpey, Gantz, Ira
Published in Diabetes, obesity & metabolism (01.04.2020)

Get full text

Journal Article

Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus

Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus

by Segar, Matthew W., Kolkailah, Ahmed A., Frederich, Robert, Pong, Annpey, Cannon, Christopher P., Cosentino, Francesco, Dagogo‐Jack, Samuel, McGuire, Darren K., Pratley, Richard E., Liu, Chih‐Chin, Maldonado, Mario, Liu, Jie, Cater, Nilo B., Pandey, Ambarish, Cherney, David Z. I.
Published in Diabetes, obesity & metabolism (01.09.2022)

Get full text

Journal Article

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

by KASTELEIN, John J. P, VAN DER STEEG, Wim A, SZAREK, Michael, LAROSA, John C, PEDERSEN, Terje R, GRUNDY, Scott M, HOLME, Ingar, GAFFNEY, Michael, CATER, Nilo B, BARTER, Philip, DEEDWANIA, Prakash, OLSSON, Anders G, MATTHIJS BOEKHOLDT, S, DEMICCO, David A
Published in Circulation (New York, N.Y.) (10.06.2008)

Get full text

Journal Article

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial

by Wojeck, Brian S., Inzucchi, Silvio E., Neeland, Ian J., Mancuso, James P., Frederich, Robert, Masiukiewicz, Urszula, Cater, Nilo B., McGuire, Darren K., Cannon, Christopher P., Yaggi, Henry Klar
Published in Sleep & breathing (01.05.2023)

Get full text

Journal Article

$Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial$

Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial

by Pandey, Ambarish, Kolkailah, Ahmed A, Cosentino, Francesco, Cannon, Christopher P, Frederich, Robert C, Cherney, David Z I, Dagogo-Jack, Samuel, Pratley, Richard E, Cater, Nilo B, Gantz, Ira, Mancuso, James P, McGuire, Darren K
Published in European heart journal (21.12.2023)

Get full text

Journal Article

481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV

481-P: Eligibility for Icosapent Ethyl in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: An Analysis of VERTIS CV

by KIM, JOSEPH M., BHATT, DEEPAK L., DAGOGO-JACK, SAMUEL, CHERNEY, DAVID, COSENTINO, FRANCESCO, MCGUIRE, DARREN K., PRATLEY, RICHARD E., LIU, CHIH-CHIN, CATER, NILO B., FREDERICH, ROBERT, MANCUSO, JAMES P., CANNON, CHRISTOPHER P.
Published in Diabetes (New York, N.Y.) (01.06.2022)

Get full text

Journal Article

Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV

Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV

by Sridhar, Vikas S., Cosentino, Francesco, Dagogo‐Jack, Samuel, McGuire, Darren K., Pratley, Richard E., Cater, Nilo B., Noyes Essex, Margaret, Mancuso, James P., Zhao, Yujie, Cherney, David Z. I.
Published in Diabetes, obesity & metabolism (02.09.2024)

Get full text

Journal Article

Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin

by Corbin, Karen D., Dagogo‐Jack, Samuel, Cannon, Christopher P., Cherney, David Z.I., Cosentino, Francesco, Frederich, Robert, Liu, Jie, Pong, Annpey, Lin, Jianxin, Cater, Nilo B., Pratley, Richard E.
Published in Diabetes, obesity & metabolism (01.03.2023)

Get full text

Journal Article

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial

by Cosentino, Francesco, Cannon, Christopher P, Frederich, Robert, Cherney, David Z I, Dagogo-Jack, Samuel, Pratley, Richard E, Mancuso, James P, Maldonado, Mario, Cater, Nilo B, Wang, Shuai, McGuire, Darren K
Published in Circulation (New York, N.Y.) (23.08.2022)

Get full text

Journal Article

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity

by Ji, Linong, Liu, Jie, Xu, Zhi Jin, Wei, Zhiqi, Zhang, Ruya, Malkani, Seema, Cater, Nilo B., Frederich, Robert
Published in Diabetes therapy (01.02.2023)

Get full text

Journal Article

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease

by Kim, Joseph M., Bhatt, Deepak L., Dagogo‐Jack, Samuel, Cherney, David Z. I., Cosentino, Francesco, McGuire, Darren K., Pratley, Richard E., Liu, Chih‐Chin, Cater, Nilo B., Frederich, Robert, Mancuso, James P., Cannon, Christopher P.
Published in Diabetes, obesity & metabolism (01.05.2023)

Get full text

Journal Article

Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial

Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial

by Tikkanen, Matti J, Szarek, Michael, Fayyad, Rana, Holme, Ingar, Cater, Nilo B, Faergeman, Ole, Kastelein, John J P, Olsson, Anders G, Larsen, Mogens Lytken, Lindahl, Christina, Pedersen, Terje R
Published in Journal of the American College of Cardiology (15.12.2009)

Get full text

Journal Article

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

by Vega, Gloria Lena, Ma, Patrick T.S, Cater, Nilo B, Filipchuk, Neil, Meguro, Shinichi, Garcia-Garcia, Ana Barbara, Grundy, Scott M
Published in The American journal of cardiology (15.04.2003)

Get full text

Journal Article

Influence of Extended-Release Nicotinic Acid on Nonesterified Fatty Acid Flux in the Metabolic Syndrome With Atherogenic Dyslipidemia

Influence of Extended-Release Nicotinic Acid on Nonesterified Fatty Acid Flux in the Metabolic Syndrome With Atherogenic Dyslipidemia

by Vega, Gloria Lena, Cater, Nilo B., Meguro, Shinishi, Grundy, Scott M.
Published in The American journal of cardiology (01.06.2005)

Get full text

Journal Article

Responsiveness of Plasma Lipids and Lipoproteins to Plant Stanol Esters

Responsiveness of Plasma Lipids and Lipoproteins to Plant Stanol Esters

by Cater, Nilo B., Garcia-Garcia, Ana-Barbara, Vega, Gloria Lena, Grundy, Scott M.
Published in The American journal of cardiology (04.07.2005)

Get full text

Journal Article Conference Proceeding